Omeros Corporation (OMER)
NASDAQ: OMER · Real-Time Price · USD
11.29
-0.25 (-2.17%)
At close: Mar 9, 2026, 4:00 PM EDT
11.29
0.00 (0.00%)
After-hours: Mar 9, 2026, 4:00 PM EDT
Omeros Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
202
Market Cap
800.47M
Revenue Chart
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| MannKind | 348.97M |
| Phathom Pharmaceuticals | 175.11M |
| Xencor | 125.58M |
| CytomX Therapeutics | 113.63M |
| Kura Oncology | 67.48M |
| Evommune | 13.00M |
| Janux Therapeutics | 10.00M |
| KalVista Pharmaceuticals | 1.43M |
OMER News
- 20 days ago - Omeros Announces Successful Primate Study in OncotoX-AML™ Drug Program - Business Wire
- 5 weeks ago - Omeros Announces First Commercial Sales of YARTEMLEA® - Business Wire
- 2 months ago - Omeros Corporation (OMER) Discusses FDA Approval and Commercialization Plans for YARTEMLEA in TA-TMA Treatment Transcript - Seeking Alpha
- 2 months ago - Omeros prices transplant complication drug at $36,000 per dose - Reuters
- 2 months ago - Omeros Announces New Date for YARTEMLEA® Approval Conference Call - Business Wire
- 2 months ago - Omeros: Stock Pops On Yartemlea Approval, Longer-Term Upside Likely - Seeking Alpha
- 2 months ago - Gold Edges Lower; Omeros Shares Jump - Benzinga
- 2 months ago - US FDA approves Omeros' drug to treat dangerous transplant complication - Reuters